Apimeds Pharmaceuticals US, Inc. (APUS)
NYSE: APUS · Pharmaceutical Preparations · Matawan, NJ · filing with the SEC since 2024
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | May 4, 2026 | Apr 15, 2025 | · |
| Research and development | 1,632,581 | · | 98,544 |
| General and administrative | 10,279,981 | 1,275,095 | 648,892 |
| Total operating expenses | 11,912,562 | 1,275,095 | · |
| Operating income | -11,912,562 | -1,275,095 | -747,436 |
| Interest expense | 283,011 | 117,719 | 38,069 |
| Interest and investment income | 107,595 | 2,824 | 7,811 |
| Total non-operating income (expense) | 5,911,425 | -114,895 | -30,258 |
| Net income | -6,001,137 | -1,389,990 | -777,694 |
| Earnings per share, basic | -0.55 | -0.18 | -0.17 |
| Earnings per share, diluted | -0.55 | -0.18 | -0.17 |
| Weighted average shares, basic | 10,881,907 | 7,903,850 | 4,598,265 |
| Weighted average shares, diluted | 10,881,907 | 7,903,850 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding